Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are relatively novel agents that are important components of treatment regimens used to treat both newly diagnosed and relapsed/refractory CLL. This evidence concerns the gene IBTK and B-cell chronic lymphocytic leukemia.